Evidence map›Paper›PMID 8055157›Full record

ArticleVirchows Archiv : an international journal of pathology1994

Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.

K Segers, M Ramael, S K Singh, J Weyler, J Van Meerbeeck, P Vermeire, E Van Marck

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Current therapy for malignant mesothelioma.Current oncology reports · 2002
    Review
  3. Poorly differentiated synovial sarcoma: a case report.Pathology oncology research : POR · 2001
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

K SegersDepartment of Pathology, University Hospital of Antwerp, University of Antwerp, Edegem, Belgium.
M Ramael
S K Singh
J Weyler
J Van Meerbeeck
P Vermeire
E Van Marck
University of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunohistochemical study of bcl-2 protein immunoreactivity in human non-neoplastic mesothelium (44 cases) and in malignant mesothelioma (62 cases) using a murine monoclonal antibody (clone 124) showed cytoplasmic immunoreactivity for bcl-2 protein in five cases of malignant mesothelioma. Non-neoplastic mesothelium was not immunoreactive. Immunoreactivity for bcl-2 protein does not add useful prognostic information in malignant mesothelioma since survival times of bcl-2 positive and bcl-2 negative cases did not differ. Nevertheless, the detection of bcl-2 protein in malignant mesothelioma might be useful for the differentiation from reactive mesothelium.

Indexed as

EpitheliumHumansImmunohistochemistryMesotheliomaProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Survival RateProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2

Identifiers

PMID8055157
OpenAlexW2075807789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.